Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 241,219,795 papers from all fields of science
Search
Sign In
Create Free Account
teneligliptin
Known as:
((2S,4S)-4-(4-(3-Methyl-1-Phenyl-1H-Pyrazol-5-yl)Piperazin-1-yl)Pyrrolidin-2-yl)(1,3-Thiazolidin-3-yl)Methanone
A long-acting, orally bioavailable, pyrrolidine-based inhibitor of dipeptidyl peptidase 4 (DPP-4), with hypoglycemic activity. Teneligliptin may also…
Expand
National Institutes of Health
Create Alert
Alert
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Evaluation of the analgesic activity of single and multiple oral doses of teneligliptin (20 mg/day), using hot air analgesiometer in healthy human volunteers: a randomized, double blind, placebo…
Maleha Butul
,
U. Pingali
,
Chandrasekhar Nutalapati
2020
Corpus ID: 212701976
Background DPP-4 inhibitors showed analgesic and anti-inflammatory activity in human and animal-studies. DPP-4 inhibitors…
Expand
2020
2020
Efficacy and Safety of Teneligliptin as Add on Therapy in Indian Type 2 Diabetes Mellitus Patients having Dyslipidemia
M. ParmarVinendra
,
S. GoswamiSunita
2020
Corpus ID: 219815212
Objectives: The purpose of this study was to investigate the efficacy and safety of teneligliptin, a completely unique and highly…
Expand
2020
2020
Comparison of teneligliptin with sitagliptin as an add on to metformin in patients of type 2 diabetes mellitus: an observational study
S. Dange
,
Nimish S. Narkar
,
P. Rane
,
Sayanna Das
,
Vishwadeep Madrewar
,
Revati Kothari
2020
Corpus ID: 219524254
Background: Teneligliptin is a new dipeptidyl peptidase-4 (DPP-4) inhibitor, available in India. It has been widely prescribed in…
Expand
2019
2019
The Efficacy and Safety of Teneligliptin and Metformin versus Glimepiride and Metformin in Patients of Type-2 Diabetes Mellitus Uncontrolled with Monotherapy
Nitika Hans
2019
Corpus ID: 202000420
Introduction: Type 2 diabetes mellitus is one of the most common non-communicable diseases associated with short term and long…
Expand
2019
2019
Efficacy of Teneligliptin as Add-on Therapy in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease: A Real-World Experience
Ram Kumar
,
A. Rathod
,
S. Suryawanshi
,
H. Barkate
,
Sujay S. Patil
2019
Corpus ID: 212478029
Introduction: Type 2 diabetes mellitus (T2DM) with chronic kidney disease (CKD) is dreadful combination necessitating adequate…
Expand
2018
2018
Teneligliptin add on to monotherapy treatment in patients with type 2 diabetes
A. K. Chatterjee
2018
Corpus ID: 54519921
Background: In patient with type 2 diabetes (T2D) inadequately controlled on monotherapy, teneligliptin is efficacious and safe…
Expand
2018
2018
An Open Label, 2 Year Long Term Follow-Up Study to Assess the Efficacy, Safety and Tolerability of Teneligliptin in Indian Subjects with Type 2 Diabetes Mellitus
S. Manjula
2018
Corpus ID: 198381044
Background: Diabetes is a significant health burden and is emerging as a pandemic. Teneligliptin, oral DPP-4 inhibitor was…
Expand
2017
2017
Role of teneligliptin in rural India as add-on third drug in patients with type 2 diabetes mellitus
C. Gupta
,
V. Raghavan
,
Sukanta Sen
,
S. Kothari
2017
Corpus ID: 54224153
Background: Teneligliptin was introduced in India in May 2015. It has gained popularity and is already widely prescribed in type…
Expand
2015
2015
Teneligliptin key intermediate preparation method
Fang Chen
,
Shu-Yun Li
2015
Corpus ID: 106112085
The present invention discloses a preparation method of a teneligliptin key intermediate 1-(3-methyl-1-phenyl-1H-pyrazol-5-yl…
Expand
2014
2014
STABILITY INDICATING RP-HPLC METHOD FOR DEVELOPMENT AND VALIDATION OF TENELIGLIPTIN HYDROBROMIDE HYDRATE IN PURE AND TABLET DOSAGE FORMS
V. Rao
,
K. Saraswathi
2014
Corpus ID: 98122970
A simple, rapid, precise and accurate isocratic reversed-phase stability-indicating HPLC method was developed and validated for…
Expand